Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
8049.HK
Strong BuyJilin Province Huinan Changlong Bio-pharmacy Company Limited · Healthcare · Hong Kong · $168M · Avg Vol: $18K/d
100
StockRankGet insider-trade alerts
Q
80
V
96
M
77
P/E (TTM)
5.1x
ROE
12.3%
D/E
0.0x
Dividend %
12.2%
COMPANY DESCRIPTION
Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products under the Changlong and Qing Tong brands in the People's Republic of China.
FINANCIAL SUMMARY (HKD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 981.7M | 981.6M | 1.0B | 1.1B | 2.3% | 1.0B |
| EPS (HKD) | 1.31 | 1.00 | 1.25 | 1.34 | 0.9% | 0.46 |
| Shares | 172.5M | 172.5M | 172.5M | 172.5M | 0.0% | 172.5M |
| Debt | 0.5M | 93.8M | 84.5M | 0.5M | 0.0% | 1.1M |
| Equity | 1.9B | 1.7B | 1.9B | 2.0B | 1.5% | — |
| Op CF | 237.9M | 368.5M | 256.2M | 365.4M | 15.4% | 365.4M |
| Inv CF | -137.6M | 127.2M | -362.7M | -267.3M | — | — |
| Fin CF | -32.3M | -217.5M | -29.2M | -206.2M | — | — |
Loading 1Y...
PRICE (1Y)-1.3%
SMA 50SMA 200
Close
$0.2998
RSI (14)
63.2
52W High
$0.3417
From 52W High
0.9%
SCORE BREAKDOWN
Quality
80
ROIC
15.4%85.7
ROE
12.3%77.7
GP/Assets
28.5%62.8
Op. Margin
34.9%94.1
FCF/Assets
11.7%89.0
Piotroski
790.7
Int. Cover
50.0x89.3
D/E Ratio
0.00x94.4
Current Ratio
1.47x26.1
Value
96
P/E (TTM)
5.1x97.4
EV/EBITDA
1.3x98.9
P/FCF
3.6x95.9
P/B
0.5x96.0
P/S
1.3x79.2
Div Yield
12.2%99.4
Momentum
77
52W High %
88%79.0
RS 6M
30%85.2
SMA 50/200
1.12x80.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
19%56.6
FUNDAMENTALS
Market Cap
$168M
P/E (Forward)
—
Gross Margin
84.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 8049.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 8049.HK | Jilin Province Huinan Changlong Bio-pharmacy Company Limited(you) | $168M | 100 | Strong Buy |
| 2348.HK | Dawnrays Pharmaceutical (Holdings) Limited | $192M | 99 | Strong Buy |
| 3839.HK | CPBIO Holding Company Limited | $270M | 96 | Strong Buy |
| 2161.HK | JBM (Healthcare) Limited | $192M | 89 | Strong Buy |
| 2633.HK | Jacobson Pharma Corporation Limited | $267M | 94 | Strong Buy |
| 0950.HK | Lee's Pharmaceutical Holdings Limited | $101M | 76 | Buy |
| 3613.HK | Beijing Tong Ren Tang Chinese Medicine Company Limited | $694M | 93 | Strong Buy |
| 2005.HK | SSY Group Limited | $994M | 82 | Strong Buy |
| 0570.HK | China Traditional Chinese Medicine Holdings Co. Limited | $893M | 69 | Buy |
| 3320.HK | China Resources Pharmaceutical Group Limited | $3.7B | 93 | Strong Buy |
Peer medians: ROE 6.3% · P/E 11.5x · Gross margin 38.1%